This strategy has been investigated, such as pooling monospecific CAR-T cells targeting human epidermal growth factor receptor-2 (HER2)/IL-13Rα2 for glioblastoma and CD19/CD123 for B-ALL [34, 35]. The gene discussed is ERBB2; the disease is glioblastoma.